Phase III Study Comparing AZD0120 and Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Patients Eligible for Transplant

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of newly diagnosed multiple myeloma (NDMM).
• Have measurable disease at diagnosis based on specific protein levels in blood or urine.
• Completed 4 to 6 cycles of initial therapy with approved regimens like anti-CD38+VRd, DVTd, DRd, or VRd.
• Achieved stable disease or better after initial therapy.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Eligible for high-dose melphalan treatment followed by a stem cell transplant.
• Have adequate organ and bone marrow function.

Exclusion Criteria

• Have or had cancer spread to the central nervous system or signs of brain involvement.
• Have primary amyloidosis, active plasma cell leukemia, Waldenstrom macroglobulinemia, or POEMS syndrome.
• Have significant neurological or psychiatric conditions.
• Have a medical condition that poses a high risk for treatment complications.
• Required additional therapy due to inadequate response to initial treatment.
• Have had prior T-cell engager therapy, CAR-T, or CAR-NK cell therapy targeting any cancer.
• Have had prior therapy targeting BCMA and CD19.